Strategies for Effective Partnerships Between Pharmaceutical and Diagnostic Companies

NEW YORK, Jan. 17, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0760610/Strategies-for-Effective-Partnerships-Between-Pharmaceutical-and-Diagnostic-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics

Introduction

This report examines the various models that are being adopted by players and uses case studies to highlight the risks and rewards of different approaches to partnerships. The challenges facing companies when entering into a collaboration and factors that should be taken into account when selecting a partner are reviewed and recommendations given as to best practices in partnering.

Features and benefits

* With the use of case studies understand the various approaches to pharma-diagnostic collaboration and decide the best fit for your company.* Evaluate the benefits and disadvantages of emerging business models and collaborative agreements for drug diagnostic co-development.* Evaluate alternative partnership models that can drive revenue growth for both diagnostic and pharma players.* Understand regulatory trends that will influence the reimbursement status of both the drug and diagnostic in any combined offering.* Learn how to get the most out of a deal from both the pharma and the diagnostic company's perspective.

Highlights

The need for tropism testing to select patients for Pfizer's maraviroc, prompted a co-development collaboration with Monogram Biosciences, that's laboratory-developed test was the only clinically validated tropism assay. The partnership underlines the need for education of physicians and the role of guidelines to support use of the assay.Prometheus achieved a five-fold increase in sales in six years for AstraZeneca's treatment for Crohn's disease, Entocort EC, by promoting its IBD serology test in conjunction with the therapy. The sales and marketing model focused on both diagnosis and treatment of irritable bowel disease, an area in which differential diagnosis is difficult.Entering into a partnership early will facilitate a coordinated approach to simultaneous approval and availability of the Rx and companion Dx. Formal working processes and dedicated project teams engender transparency and good communication channels between both partners.

Your key questions answered

* What are the different approaches to forming alliances between diagnostic and pharma companies and which have proved most successful and why?* What are the main challenges in forming alliances between pharma and diagnostic companies and how can these be overcome?* How can both the diagnostic and pharmaceutical company ensure that they benefit from any alliance?* How can I form successful alliances with non-traditional partners such as contract research organizations and pharmacy benefit managers?* How should I go about gaining reimbursement for my diagnostic test?

The personalized medicine paradigmCo-development partnershipsRetrospective development alliancesAlternative partnership modelsBest practices in RxDx partneringFuture trends influencing RxDx partnershipsAbout the authorDisclaimerThe personalized medicine paradigmSummary

Drivers of Rx/Dx partnershipsRegulatory driversEU regulatory initiativesA convergence of different industry sectorsPartnership trendsScope of reportCo-development partnershipsSummary

Genentech/Dako: Herceptin/HercepTestThe partnershipThe resultsObservationsPfizer/Monogram Biosciences: Selzentry/TrofileThe partnershipResultsObservationsPlexxikon/Roche: Zelboraf/BRAF testThe partnershipResultsObservationsBayer Schering/PrometheusThe partnershipObservationsNovartis/Invivoscribe: midostaurin/FLT3The partnershipObservationsRetrospective development alliancesSummary

Vectibix/Erbitux:KRASThe partnershipsObservationsIressa (AstraZeneca)/QiagenThe partnershipObservationsAlternative partnership modelsSummary

Prometheus/EntocortThe partnershipThe resultsObservationsTakeda/Zinfandel: pioglitazone/TOMM40 assayBackgroundThe partnershipObservationsGSK/Enigma DiagnosticsThe partnershipObservationsDako/QuintilesBackgroundThe partnershipObservationsMedco/MolecularMDThe partnershipObservationsBest practices in RxDx partneringSummary

What are pharma companies looking for?What are Dx companies looking for?Negotiating the dealIngredients of a successful relationshipStart earlySharing a common goalMutual understanding of different business modelsUnderstanding risksGood working processesReimbursementCommercializationFuture trends influencing RxDx partnershipsSummary

Industry dynamicsRegulators take proactive rolePricing and reimbursement environmentUK Stratified Medicine initiativeAppendixBibliography/ReferencesAbbreviations

More  

Check our  

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker